Vemlidy Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber managing patients with chronic hepatitis B, you are likely aware that Vemlidy (tenofovir alafenamide, TAF) has become increasingly difficult for patients to access at standard retail pharmacies. While this is not a traditional manufacturing shortage, the practical impact on patient care is real and growing. This briefing covers the current availability picture, prescribing implications, cost and access barriers, and tools you can use to help your patients maintain uninterrupted antiviral therapy.

Current Availability Status (Early 2026)

Vemlidy is NOT on the FDA Drug Shortage Database as of early 2026. Gilead Sciences maintains supply through its specialty distribution network. However, access challenges are driven by structural factors:

Retail pharmacy stocking: Limited. Most chain retail pharmacies do not routinely stock Vemlidy due to its high unit cost (~$1,500–$1,800/month) and relatively low dispensing volume.

Specialty pharmacy availability: Generally reliable. CVS Specialty, Walgreens Specialty, Accredo, and Biologics by McKesson typically carry Vemlidy.

Mail-order: Available through most plans' specialty mail-order services.

Generic status: No US-marketed generic. The FDA has approved generic manufacturing, but no standalone generic TAF product is available commercially in the US as of early 2026.

Clinical Context and Prescribing Implications

Vemlidy was FDA-approved in November 2016 for adults with chronic HBV and compensated liver disease, expanded to adolescents ≥12 years in 2022 and to children ≥6 years weighing ≥25 kg in 2024. It is recommended by both AASLD and EASL as a preferred first-line agent for chronic HBV.

Key clinical advantages over TDF:

Improved renal safety — significantly better eGFR preservation and lower rates of proximal tubular dysfunction

Improved bone safety — less bone mineral density loss; preferred for patients with osteoporosis or fragility fracture history

Comparable antiviral efficacy — 8-year data show 91–97% maintained undetectable HBV DNA; no resistance developed in sequenced patients

Lower systemic tenofovir exposure at 10x lower dose (25 mg TAF vs. 300 mg TDF)

Managing Prior Authorization for Vemlidy

Some payers require step therapy through TDF or entecavir before authorizing Vemlidy, particularly for commercially insured patients without documented renal or bone concerns. Effective PA documentation includes:

Baseline or declining eGFR and/or creatinine elevation on TDF

DXA scan results showing bone mineral density loss or osteoporosis

History of fragility fractures or age-related bone risk factors

Prior TDF intolerance or nephrotoxicity

Citation of AASLD/EASL guidelines preferring TAF in patients with renal or bone concerns

For Medicare patients: Most Part D plans list Vemlidy on Tier 5. Manufacturer co-pay assistance programs are not available for Medicare patients, so plan-based coverage is the primary financial mechanism. Ensure patients are aware of the catastrophic coverage threshold under the Inflation Reduction Act's $2,000 OOP cap (Part D, 2025+).

Bridging Options If a Patient Cannot Access Vemlidy

If a patient cannot access Vemlidy due to a coverage gap, prior authorization delay, or cost barrier, the recommended bridging options are:

Tenofovir disoproxil fumarate (TDF, 300 mg daily) — the most direct bridge with the same active metabolite. Use with caution in patients with renal impairment or bone concerns.

Entecavir (0.5 mg daily for treatment-naive) — safe and effective alternative; preferred in patients with tenofovir-related renal concerns; must be taken on empty stomach.

Critical reminder: Never advise patients to simply stop Vemlidy. Discontinuation can precipitate severe acute hepatitis B exacerbation (boxed warning). Monitor liver function closely for at least several months after any treatment interruption.

Key Drug Interactions to Screen Before Prescribing

Vemlidy is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Major interactions to screen:

Avoid concurrent use: Rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, oxcarbazepine, St. John's wort (P-gp/BCRP inducers that reduce TAF levels)

Use with caution: Cyclosporine (P-gp/BCRP inhibitor); high-dose NSAIDs (increased nephrotoxicity risk with tenofovir)

Do not co-prescribe: Other tenofovir-containing products (Biktarvy, Descovy, Genvoya, Truvada, Viread, etc.) — duplicate tenofovir exposure risk

Required Monitoring for Patients on Vemlidy

Per prescribing information, the following monitoring is required at initiation and on a clinically appropriate schedule during treatment:

HIV testing before initiating Vemlidy — do not use as sole HBV therapy in HIV-positive patients

Serum creatinine, eGFR, urine glucose, and urine protein in all patients

Serum phosphorus in patients with chronic kidney disease

HBV DNA and liver function tests per standard HBV management guidelines

Tools for Providers: Helping Your Patients Find Vemlidy

If patients report difficulty finding Vemlidy in stock, medfinder for Providers offers a tool that calls pharmacies in a patient's area to find which ones have the medication in stock. This can be a valuable addition to your practice workflow, particularly for patients who are new to specialty pharmacy navigation or who live in areas with limited specialty pharmacy access.

For a step-by-step workflow guide, see our related article: How to Help Your Patients Find Vemlidy in Stock: A Provider's Guide.